A2ML1

Across TCGA pan-cancer cohorts, A2ML1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated A2ML1 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher A2ML1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated A2ML1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where A2ML1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.233	0.432	.006	15	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.816	.023	6	view →
LUAD	DFS	Tertile	II,III,IV	1.000	0.322	.036	6	view →
HNSC	DFS	Quartile	III,IV	0.760	0.482	.036	2	view →
UCEC	OS	Tertile	All	1.000	0.887	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

A2ML1–PDAC (DFS)

Open the PDAC breakdown →